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Introduction: Newfoundland and Labrador (NL) has the highest prevalence of cardiovas-
cular disease (CVD) in Canada. Dyslipidemia is a risk factor for CVD. This study compares
the prevalence of dyslipidemia in the NL population with the rest of Canada.
Methods: A cross-sectional study, using data from the Canadian Primary Care Sentinel
Surveillance Network (CPCSSN), was undertaken. The study population included adults,
excluding pregnant women, aged 20 years and older. Canadian guidelines were used for
classifying dyslipidemia. Univariate and multivariate analyses were conducted to compare
the lipid levels and prevalence of dyslipidemia between NL and the rest of Canada.
Results: About 128,825 individuals (NL: 7,772; rest of Canada: 121,053) were identified
with a mean age of 59 years (55% females). Mean levels of total cholesterol (4.96 vs. 4.93,
p=0.03), low-density lipoprotein (LDL) (3.00 vs. 2.90 mmol/L, p<0.0001), triglyceride (1.47
vs. 1.41 mmol/L, p<0.0001), and high-density lipoprotein (HDL) (1.29 vs. 1.39 mmol/L,
p<0.0001) were significantly different in NL compared to the rest of Canada. Dyslipi-
demias of LDL (29 vs. 25% p<0.0001), HDL (38 vs. 27%, p<0.0001), and triglyceride
(29 vs. 26%, p<0.0001) were significantly more common in NL. After adjustment for con-
founding variables, NL inhabitants were more likely to have dyslipidemia of total cholesterol
(OR: 1.16, 95% CI: 1.10–1.23, p<0.0001), HDL (OR: 1.52, 95% CI: 1.44–1.60, p< 0.0001),
LDL (OR: 1.38, 95% CI: 1.30–1.46, p< 0.0001), and ratio (OR: 1.53, 95% CI: 1.42–1.60,
p<0.0001).
Conclusion:The NL population has a significantly higher rate of dyslipidemia compared to
the rest of Canada, and the mean levels of all lipid components are worse in NL. Distinct
cultural and genetic features of the NL population may explain this, accounting for a higher
rate of CVD in NL.
Keywords: dyslipidemia, Canada, Newfoundland, lipid profile, prevalence, Canadian Primary Care Sentinel
Surveillance Network
INTRODUCTION
Cardiovascular diseases (CVDs) are the leading cause of death
worldwide, resulting in more than 17.3 million deaths in 2008
(1). This number is expected to reach 23.3 million in 2030
(2). Geographic variations in cardiovascular mortality have fre-
quently been reported in previous studies. According to the 2008
report by WHO, the age standardized CVD mortality rates in
the developed world (Australia, Japan, France, and United States)
has been 100–200/100,000 population in contrast to higher rates
in the rest of the world (3). The 2014 update on the bur-
den of CVD reports significant regional differences in the age
standardized cardiovascular mortality rates across the European
continent, including lower rates of 150–180 deaths/100.000 in
western European countries (Netherlands, Norway, France, and
Switzerland), higher rates among southern countries of Europe
such as Greece (246.7/100.000) and Cyprus (219.2/100.000), and
rates of above 500/100.000 in eastern European countries (Russia,
Romania, and Ukraine) (4).
In Canada, CVD is the main cause of death at 32% and,
after musculoskeletal diseases, has the highest economic burden
of disease (5). Compared to other provinces, Newfoundland and
Labrador (NL) has the highest level of CVD morbidity and mor-
tality in adults. Between 1995 and 1998 in NL, age standardized
CVD rates per 100,000 populations ranged from 320.6/100,000 to
196.9/100,000 (6). During the same period, NL had the highest life
expectancy lost (LEL) due to CVD – more than 5.3 years – in all of
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Canada (7). According to a Statistics Canada report in 2007, NL
had the highest age standardized mortality rate for major CVDs
among all Canadian provinces: 218.5/100,000 population in NL
compared to a nationwide average mortality rate of 151.9/100,000
(8). The NL CVD mortality rates are more similar to those of
southern European countries as well as low and middle income
countries, which have a higher mortality rates compared to the
developed world (3, 4).
Although regional variations in CVD and CVD morality have
been recognized, the explanation for these differences is still
unclear. Some studies suggest that these variations could be related
to the variations in cardiovascular risk factors including smok-
ing, obesity, hypertension, and dyslipidemia (9, 10). Dyslipidemia,
defined as abnormal blood lipid levels, includes elevated total
cholesterol, low-density lipoprotein (LDL), and triglyceride, and
decreased high-density lipoprotein (HDL) is one of the most
important and well-known risk factors of CVDs (11). The risk
for CVD conferred by dyslipidemia varies according to the type of
condition and presence or absence of other risk factors. It has been
reported to be one of the most important determinants of myocar-
dial infarctions among adults of young age (12). Dyslipidemia is a
multifactorial trait wherein environmental and behavioral factors,
as well as genetic predisposition, play a role (13).
Although Canada, in general, has a diversity of cultures and
ethnicities, the present NL population almost entirely originates
from 20,000 migrants from south-west England and the south of
Ireland in the mid-1700s (14). This founding population experi-
enced a low level of in-migration over the centuries, which resulted
in NL being one of the few remaining isolated Caucasian popu-
lations worldwide (14). This isolation has shaped a unique and
homogenous culture and genetic background, both of which may
contribute to the prevalence of complex traits such as dyslipi-
demia and, consequently, CVD (14). It is also notable that there is
anecdotal evidence from family physicians in NL, who worked in
different provinces that a different pattern of lipid profiles and a
higher prevalence of dyslipidemia exists in NL compared to other
Canadian provinces.
Dyslipidemia in NL has been previously documented in several
reports. School-aged children in the 1980s had higher total choles-
terol levels compared to age, sex, and racially matched American
children (15). A 1990s’ study on the rural Newfoundland popu-
lation found that 61% of the subjects had hypercholesterolemia
recorded in their medical records (16). A recent study on a sample
of 4,424 primary health-care patients in NL reported that 42%
of the patients had high cholesterol, 36% high LDL, 25% low
HDL, and 25% abnormal triglyceride; however, the results were
not compared with other populations (17). The lack of compari-
son groups, lack of biochemical measurement, and cohorts, which
were not fully representative of the NL population were limitations
of these studies. The purpose of the current study is to compare
the prevalence of dyslipidemias in residents of NL and compare
these with the rest of Canada.
MATERIALS AND METHODS
SOURCE OF DATA
The Canadian Primary Care Sentinel Surveillance Network (CPC-
SSN) is a pan-Canadian network that extracts data from the
electronic medical records (EMRs) of family physicians. At the
time of this study, the CPCSSN database included data from
close to 600 primary care clinicians in rural and urban settings
across 10 provinces of Canada. CPCSSN is Canada’s first library
of digital information based on point-of-care data from primary
care practices. Data from these EMRs are extracted quarterly and
uploaded in a de-identified format to both regional and central
(pan-Canadian) databases. The databases are used for chronic dis-
ease surveillance in primary care and are also used as a tool for
conducting primary care research (18). At the time of this study,
the pan-Canadian CPCSSN database included 844,592 individuals
over 20 years of age, corresponding to 3% of the Canadian popula-
tion; the NL component included 46,588 individuals, representing
11% of the NL population (18).
STUDY POPULATION
All adults over 20 years of age (excluding pregnant women) from
the CPCSSN database who had a lipid profile in the CPCSSN
database between January 1, 2010 and December 31, 2012 were
included in the study. To identify pregnant women, the text




Canadian guidelines for the diagnosis and management of dys-
lipidemia (20), the nationwide protocol for all practitioners in
Canada, suggests a lipid screen for all men over 40 years of age, all
women of over 50 years, all postmenopausal women, all individ-
uals with diabetes, hypertension, obesity, first degree relative with
history of CVD under the age of 60, as well as current smokers.
The routine screening test requires the measurement of all lipid
components.
In this study, the most recent lipid profiles (total cholesterol,
HDL, LDL, and triglyceride) for each individual were recorded.
The ratio of total cholesterol to HDL was calculated by divid-
ing total cholesterol by HDL. Dyslipidemia was defined using
the Canadian guidelines for the diagnosis and treatment of dys-
lipidemia (Table 1) (20). Individuals with at least one abnormal
component were classified as those with any dyslipidemia.
Geographic variables
In Canada, a national six-digit postal code is used to identify a
geographic location. Each postal code is unique and represents a
location in the real world. The first digit is specific to each province,
whereas the second one classifies the region as rural or urban.
Accordingly, we used the first digit of the postal codes to separate
those patients living in NL from those in the rest of Canada, and
Table 1 | Healthy levels of serum lipids for Canadian adults (20–23).
Total cholesterol <5.2 mmol/L (20–79 years)
Triglyceride <1.7 mmol/L
Low-density lipoprotein-cholesterol (LDL) <3.4 mmol/L
High-density lipoprotein-cholesterol (HDL) >1.0 mmol/L men; >1.3 mmol/L
women
Ratio of total cholesterol to HDL <5.0
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the second digit to classify individuals as rural or urban residents
(24). The rural/urban residence was included in the multivariate
analysis as previous studies suggest that the CVD risk factors could
differ between the rural and urban inhabitants (25).
Covariates
To account for confounding factors, CVD risk factors as well as
other variables with effect on lipid levels were extracted from
the EMR (20). The demographic variables included age and gen-
der. Obesity was defined as BMI ≥30; whereas those with BMI
lower than 30, but higher than 25 were classified as overweight.
The smoking status was extracted from the most recent record
by the family physician at the time of the lipid test, and indi-
viduals were classified as non-smokers, past smokers, and current
smokers. CPCSSN algorithms for chronic conditions were used
to ascertain both diabetes and hypertension (26). These algo-
rithms have high sensitivity and specificity to detect diabetes
and hypertension (26). Diagnostic text and ICD code records
related to these conditions in EMRs were used for other chronic
conditions, including dyslipidemia and CVD (27, 28). Medica-
tion use was identified using the text record of the medica-
tion name and/or anatomical therapeutic chemical (ATC) codes.
Usage of lipid modifying agents (HMG-CoA reductase inhibitors,
fibrates, bile acid sequestrants, nicotinic acid, and other agents)
was stratified into three categories: current users (any record of
lipid-lowering medication use before the date of a blood test
and continuing until up to the time of the blood test); pre-
vious users (record of drug use between 2 years and 3 months
before the date of the blood test); and non-users (no drug use
for the last 2 years before the date of a blood test). The clas-
sification of medication use here has been previously used in
other studies involving the study of lipid profile databases (29).
Medications with unintended effects on lipid levels (30) includ-
ing thiazides, loop diuretics, beta blockers, alpha blockers, ACE
inhibitors, calcium channel blockers, estrogen, progesterone, hor-
mone replacement therapy, and corticosteroids were extracted
from EMRs.
STATISTICAL ANALYSIS
Characteristics of the study population, as well as the mean and
confidence intervals of the individual lipid components, were sum-
marized using descriptive statistics. Classical tests of hypothesis
including Student’s t -test and the chi-squared test were conducted
to test for the association between variables. Logistic regression
modeling was used to examine the association between dyslipi-
demia and living in NL while controlling for age, sex, rurality, and
other potential influential factors. For variables with more than
5% of missing information, i.e., smoking (~70% missing) and BMI
(~50% missing), a code for missing values was considered wher-
ever model based analyses were performed. In the model, age was
classified into three groups and each group was compared against
the oldest one (Age> 65); smoking variables were compared with
non-smokers; overweight and obese patients were compared with
normal and underweight individuals; non-medication users and
previous medication users were compared with current users as
baseline. A subgroup analysis was also performed to investigate
how the patients of EMR primary care in NL differ from the
patients of EMR primary care in the rest of Atlantic Canada. A
p-value <0.05 was considered statistically significant. All analy-
ses were performed using STATA/SE 11.2 (Stata Corp., College
Station, TX, USA). Geographical variation in the prevalence of
dyslipidemia was also presented using ArcMap 10.0 (Build 4000).
ETHICS
The study protocol was approved for ethics by Health Research
Ethics Authority (HREA) of Newfoundland and Labrador.
RESULTS
POPULATION DESCRIPTION
Among the 430,169 individuals recorded in the CPCSSN database
from January 1, 2010 to December 31, 2012, 128,825 individuals
(~30%) had completed blood testing and met the study crite-
ria. The mean age was 59 years, 55% were women, and 77% were
living in an urban area. The majority of the population (78%)
was not taking any lipid-lowering medications, whereas 8 and
14% were categorized as previous users and current users, respec-
tively. Among the drug users, HMG-CoA reductases (Statins) were
the most commonly used form of lipid-lowering drugs (94%),
while other drug consumption was rare (data not shown). Table 2
presents general characteristics of the study population in NL and
the rest of Canada.
COMPARISON OF LIPID LEVELS AND DYSLIPIDEMIA IN NL WITH THE
REST OF CANADA
Mean levels for all lipid components in NL and the rest of Canada
are presented in Table 3. There are significant differences between
NL and the rest of Canada for all of the lipid components. Approx-
imately 72% of the NL population have at least one abnormal lipid
component (any dyslipidemia), whereas this figure is 64% in the
rest of Canada (p< 0.0001). Figure 1 illustrates the prevalence of
dyslipidemia in NL and the rest of Canada. Prevalence of abnormal
Table 2 | Characteristics of study population in Newfoundland and








Age [(mean (95% CI)] 58.3 (58.0–58.6) 59.2 (59.1–59.3) <0.0001
Body mass index [(mean
(95% CI)]
30.3 (29.8–30.9) 28.1 (28.0–28.1) <0.0001
Sex (female) 55.8 50.1 0.70
Residence (rural) 25.1 22.6 <0.0001
Smoking (current) 22.4 13.5 <0.0001
Smoking (past) 22.1 42.8 <0.0001
Hypertension 33.5 34.0 0.39
Diabetes 16.2 15.3 0.04
History of dyslipidemia 39.9 20.7 <0.0001
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Table 3 | Mean levels of lipid components in Newfoundland and
Labrador and the rest of Canada [mean (95% confidence interval)].
Newfoundland
and Labrador
Rest of Canada p-value
(t -test)
Total cholesterol 4.96 (4.94–4.98) 4.93 (4.93–4.94) 0.034
Low-density lipoprotein 3.00 (2.98–3.02) 2.90 (2.89–2.91) <0.0001
High-density lipoprotein 1.29 (1.28–1.30) 1.39 (1.39–1.40) <0.0001
Triglyceride 1.47 (1.45–1.49) 1.41 (1.40–1.42) <0.0001
Ratio 4.06 (4.04–4.09) 3.76 (3.75–3.77) <0.0001
FIGURE 1 | Percentage of adults with unhealthy levels of lipids in
patients of primary care in Newfoundland and Labrador and the rest of
Canada. NL, Newfoundland and Labrador.
LDL (29 vs. 25%), HDL (38 vs. 27%), triglyceride (29 vs. 26%),
and ratio (20 vs. 14%) were significantly higher in NL (p< 0.0001).
The greatest difference was observed for HDL dyslipidemia with
an 11% difference (Figures 1 and 3).
COMPARISON OF DYSLIPIDEMIA IN NL WITH REST OF CANADA
CONTROLLING FOR COVARIATES
Table 4 shows the results of the multivariate logistic regression
model for dyslipidemia. After adjusting for the effect of covari-
ates, NL inhabitants were more likely to have dyslipidemia of total
cholesterol (OR: 1.16, 95% CI: 1.10–1.23, p< 0.0001), HDL (OR:
1.52, 95% CI: 1.44–1.60, p< 0.0001), LDL (OR: 1.38, 95% CI:
1.30–1.46, p< 0.0001), and total cholesterol/HDL ratio (OR: 1.53,
95% CI: 1.42–1.60, p< 0.0001).
High-density lipoprotein dyslipidemia was significantly more
common in adults <40 years old (OR: 2.10, 95%CI: 1.99–2.23,
p< 0.0001) compared to other age groups. The greatest effect
on the dyslipidemias of all components was observed by lipid-
lowering medications (except for HDL and triglyceride) followed
by age and body mass index. Drugs with unintended lipid effects
had no significant influence on lipid levels. Further analysis on the
lipid levels was performed using linear regression modeling and
findings with similar trends were observed (data not shown).
COMPARISON OF DYSLIPIDEMIA BETWEEN NL AND ATLANTIC
CANADA
Our data identified 25,409 individuals from Atlantic Canada,
New Brunswick, Nova Scotia, Prince Edward, and NL. The NL
population had significantly higher levels of total cholesterol (4.96
vs. 4.83,p< 0.0001), LDL (3.00 vs. 2.88,p< 0.0001), and total cho-
lesterol/HDL ratio (4.06 vs. 3.99, p= 0.04) compared to the rest of
Atlantic Canada. No significant difference was observed between
NL and the other Atlantic Canadian provinces for triglyceride and
HDL levels.
Compared to the rest of Atlantic Canada, the NL population
had a higher prevalence of total cholesterol dyslipidemia (40 vs.
37%, p< 0.0001), HDL dyslipidemia (38 vs. 37%, p= 0.04), LDL
dyslipidemia (30 vs. 27%, p< 0.0001), and non-significant trends
toward higher triglyceride dyslipidemia, and ratio dyslipidemia.
The results did not change after adjustment for covariates using
multivariate logistic regression (data not shown). Distribution
of those with any dyslipidemia as well as HDL dyslipidemia in
these patients in NL and the four Canadian regions including
Atlantic Canada, Central Canada, Prairies, and Pacific Canada are
illustrated in Figures 2 and 3, respectively.
DISCUSSION
Our study included a large population of individuals who visited
family physicians in NL and across Canada. To our knowledge,
this is the first study comparing biochemical measurements of
lipid profiles between two large populations from NL and the rest
of Canada. The prevalence of dyslipidemia in NL is significantly
higher compared to the rest of Canada with the greatest differ-
ence found for HDL dyslipidemia. This might suggest that the
actual differences in dyslipidemia are much higher than what was
observed in our study. HDL levels are not generally influenced
by the common therapeutic agents administered for the manage-
ment of dyslipidemia (21). This is also consistent with the finding
from multivariate models in our study where a weak association
is reported between lipid-lowering medications and HDL. More-
over, the adults in our study who were younger than 40 years of age
were more likely to have lower HDL level compared to the adults
of other age groups. Although this might be related to the possi-
bility that the younger individuals in our study are from a high
risk group, further investigation of the associated factors of lower
HDL level among this age group could be an area of concentration
for future studies.
This study has some limitations. It is a secondary analysis of
EMR data from primary care practices in Canada. EMR data are
collected for clinical practice and the extent to which this data
could be accurate for research could be questioned. Furthermore,
we used a cross-sectional study design, which meant to provide
a snapshot of dyslipidemia in Canada. The casual/temporal rela-
tionship between lipid abnormalities and their risk factors should
be interpreted with caution. The negative association between
dyslipidemia and morbidities including CVD, diabetes, and hyper-
tension should be interpreted in the line of a therapeutic regime
suggested by the CVD prevention guidelines for patients with those
conditions (20).
Electronic medical records are becoming more commonly used
in medical practice; however, the quality of EMR data may not be
optimal. A systematic review on use of EMR for health outcome
research suggests that the validity of EMR data differs from coun-
try to country and from health condition to health condition (31).
A recent study by Tu et al. assessed the completeness of primary
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FIGURE 2 | Geographic distribution of those with any dyslipidemia in primary care patients in Canada.
FIGURE 3 | Geographic distribution of HDL dyslipidemia in primary care patients in Canada.
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Table 4 | Multivariable logistic regression models assessing lipid abnormalities between Newfoundland and Labrador compared to the rest of
Canada [odds ratio (95% confidence interval)].
Total cholesterol LDL HDL Triglyceride Total cholesterol/
HDL ratio
Newfoundland and Labrador 1.16 (1.10, 1.23) 1.38 (1.30, 1.46) 1.52 (1.44, 1.60) 1.03 (0.98, 1.09)NS 1.53 (1.44, 1.63)
Sex (females) 1.70 (1.65, 1.75) 1.00 (0.97, 1.03)NS 1.90 (1.85, 1.96) 0.59 (0.57, 0.61) 0.35 (0.34, 0.37)
Age (40–65) 0.92 (0.89, 0.95) 1.06 (1.03, 1.10) 1.39 (1.34, 1.44) 1.20 (1.16, 1.24) 1.84 (1.77, 1.91)
Age (<40) 0.38 (0.36, 0.40) 0.54 (0.51, 0.57) 2.10 (1.99, 2.23) 1.39 (1.31, 1.48) 1.66 (1.55, 1.77)
Past smokers 1.03 (0.98, 1.09)NS 1.03 (0.97, 1.09)NS 1.02 (0.96, 1.09)NS 1.02 (0.96, 1.08)NS 1.00 (0.92, 1.08)NS
Current smokers 1.03 (0.95, 1.11)NS 1.17 (1.08, 1.27) 1.45 (1.34, 1.58) 1.59 (1.47, 1.72) 1.84 (1.67, 2.02)
Overweight 1.14 (1.08, 1.20) 1.49 (1.40, 1.58) 1.82 (1.70, 1.95) 2.23 (2.07, 2.4) 1.86 (1.72, 2.01)
Obese 0.86 (0.82, 0.91) 1.34 (1.26, 1.43) 2.99 (2.79, 3.20) 4.13 (3.85, 4.44) 2.96 (2.74, 3.19)
Rural residence 0.86 (0.83, 0.89) 0.91 (0.88, 0.94) 1.09 (1.05, 1.13) 1.29 (1.25, 1.34) 1.22 (1.17, 1.26)
Diabetes 0.32 (0.31, 0.34) 0.39 (0.37, 0.42) 1.68 (1.61, 1.75) 2.47 (2.37, 2.57) 1.07 (1.02, 1.12)c
Hypertension 0.86 (0.83, 0.89) 0.88 (0.84, 0.91) 1.00 (0.96, 1.04)NS 1.46 (1.40, 1.51) 1.14 (1.09, 1.19)
Cardiovascular disease 0.91 (0.88, 0.95) 0.93 (0.89, 0.97) 1.13 (1.09, 1.18) 1.08 (1.04, 1.13) 1.05 (1.01, 1.10)c
Lipid-lowering (previous user) 1.88 (1.75, 2.01) 2.08 (1.91, 2.27) 0.96 (0.90, 1.02)NS 0.96 (0.91, 1.02) 1.59 (1.47, 1.73)
Lipid-lowering (non-user) 5.35 (5.08, 5.63) 4.78 (4.48, 5.10) 0.80 (0.76, 0.83) 0.51 (0.49, 0.53) 2.13 (2.00, 2.26)
Drugs with unintended lipid effects 1.03 (1.00, 1.07)NS 1.01 (0.97, 1.05)NS 1.07 (1.03, 1.11) 1.01 (0.98, 1.05)NS 0.94 (0.90, 0.98)c
Low-density lipoprotein – – 0.72 (0.71, 0.73) – –
Triglyceride 2.14 (2.10, 2.18) 1.59 (1.56, 1.63) 2.67 (2.62, 2.73) – –
High-density lipoprotein – 1.34 (1.29, 1.40) – – –
Total cholesterol – – – 1.93 (1.90, 1.96) –
All the presented odds ratios are significant at p<0.0001 except for cp<0.05, NSnot significant (p>0.05).
care EMR data in Ontario, Canada. The study shows good capture
of information and low level of missing information within pri-
mary care EMRs compared with administrative data (32). Another
study using data from CPCSSN shows high validity and reliability
for eight common chronic conditions in primary care CPCSSN
data. The study suggests that CPCSSN data are a suitable source
for health service research (33).
Statistics Canada surveys could be a complement to the EMR
data that we used in the study, as the best measure for examining
the discrepancies in lipid profiles between different communities
and geographic regions. Especially, if it is argued that our results
only correspond to a portion of the population who had a lipid
profile conducted by their family physician; generally speaking, a
population with higher morbidity.
This study, however, is the first of its kind to compare a large
population from NL and the rest of Canada (11 and 3% of the
overall population, respectively), and the findings show strong
similarities with lipid levels of Canadians as reported from the
Canadian Health Measure Surveys (22, 23, 34, 35), in serum lev-
els of total cholesterol (4.94 vs. 4.93), LDL (2.91 vs. 2.90), HDL
(1.39 vs. 1.41), triglyceride (1.42 vs. 1.35), and ratio (3.79 vs. 3.77)
as well as the prevalence of dyslipidemia (22) of total cholesterol
(both 40%), LDL (both 26%), HDL (28 vs. 25%), and ratio (14
vs. 16%), respectively. Findings from our previous study in NL,
using secondary data from NL laboratories on a sample of 94,000
adults 20 years and older who had lipid profile tests between 2009
and 2010, also showed similarities with the present study (36).
Both of these reports support differences in lipid levels and the
higher prevalence of dyslipidemia in NL, particularly for HDL
dyslipidemia.
IMPLICATIONS FOR CLINICAL PRACTICE
The fundamental research idea came from experienced clinicians
in several Canadian provinces who suspected an abnormality in
Newfoundlanders’ lipid profiles. Our results are in agreement with
their speculations. The observed differences in the prevalence of
dyslipidemia in our study will have clinical benefits in designing
guidelines for the treatment and prevention of dyslipidemia and
CVD, as well as in identifying the contributing factors in a distinct
population such as NL, where the current therapeutic and pre-
vention guidelines might not be as effective and applicable. This
is particularly of importance for HDL-C, which is known to be a
key determinant of CVD risks, which even persists among patients
with low levels of LDL-C (37).
The findings in our study are also consistent with previous
studies suggesting regional differences in the prevalence of dys-
lipidemia in different regions of Europe (38) and among Hispanic
and non-Hispanic whites populations in USA (39). These stud-
ies suggested a more aggressive management of the risk factors in
the afflicted areas. Such a strategy could also be considered by the
authorities in NL province of Canada.
CONCLUSION
Analyses of the CPSSN data indicate a significantly higher preva-
lence of adverse lipid components in NL compared to the rest of
Canada, including a higher prevalence of low HDL in NL.
It is difficult to determine exactly what the lower HDL levels in
younger adults and unhealthy levels of lipids in adults generally
mean for CVD prevalence in the future as the individuals age; how-
ever, it may be an indication that the high rate of CVD in NL is not
likely to change any time soon. The results of this study provide
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more evidence of our theory that a different pattern of serum
lipids is present in NL, which has a homogenous population, and
suggests that more research into lipid profiles is required, espe-
cially with regard to the effects of HDL on cardiovascular health
in that population. Our findings will be beneficial in designing
guidelines for the treatment and prevention of dyslipidemia and
CVD, as well as in identifying the contributing factors specific to
NL population.
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